## Jeanne E Hendrickson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6189550/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation. Blood, 2010, 115, 4284-4292.	1.4	449
2	Noninfectious Serious Hazards of Transfusion. Anesthesia and Analgesia, 2009, 108, 759-769.	2.2	360
3	Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non–transferrin-bound iron. Blood, 2011, 118, 6675-6682.	1.4	267
4	American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Advances, 2020, 4, 327-355.	5.2	241
5	Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells. Transfusion, 2006, 46, 1526-1536.	1.6	161
6	Inflammation enhances consumption and presentation of transfused RBC antigens by dendritic cells. Blood, 2007, 110, 2736-2743.	1.4	126
7	Implementation of a pediatric trauma massive transfusion protocol: one institution's experience. Transfusion, 2012, 52, 1228-1236.	1.6	123
8	Transfusion-related red blood cell alloantibodies: induction and consequences. Blood, 2019, 133, 1821-1830.	1.4	116
9	Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series. Transfusion, 2016, 56, 107-114.	1.6	111
10	A novel mouse model of red blood cell storage and posttransfusion in vivo survival. Transfusion, 2009, 49, 1546-1553.	1.6	106
11	Incidence of transfusion reactions: a multicenter study utilizing systematic active surveillance and expert adjudication. Transfusion, 2016, 56, 2587-2596.	1.6	103
12	Coagulopathy is Prevalent and Associated with Adverse Outcomes in Transfused Pediatric Trauma Patients. Journal of Pediatrics, 2012, 160, 204-209.e3.	1.8	100
13	Bridging channel dendritic cells induce immunity to transfused red blood cells. Journal of Experimental Medicine, 2016, 213, 887-896.	8.5	89
14	Strainâ€specific red blood cell storage, metabolism, and eicosanoid generation in a mouse model. Transfusion, 2014, 54, 137-148.	1.6	87
15	Hemolytic Disease of the Fetus and Newborn: Modern Practice and Future Investigations. Transfusion Medicine Reviews, 2016, 30, 159-164.	2.0	85
16	Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study ( <scp>REDS</scp> â€ <scp>III</scp> ) database. British Journal of Haematology, 2018, 181, 672-681.	2.5	85
17	Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs. Blood, 2012, 119, 1566-1569.	1.4	75
18	A murine neonatal model of necrotizing enterocolitis caused by anemia and red blood cell transfusions. Nature Communications, 2019, 10, 3494.	12.8	74

#	Article	IF	CITATIONS
19	Understanding red blood cell alloimmunization triggers. Hematology American Society of Hematology Education Program, 2016, 2016, 446-451.	2.5	72
20	IMMUNOHEMATOLOCY: Storage of murine red blood cells enhances alloantibody responses to an erythroidâ€specific model antigen. Transfusion, 2010, 50, 642-648.	1.6	71
21	Factors Influencing RBC Alloimmunization: Lessons Learned from Murine Models. Transfusion Medicine and Hemotherapy, 2014, 41, 406-419.	1.6	71
22	Immunophenotypic parameters and <scp>RBC</scp> alloimmunization in children with sickle cell disease on chronic transfusion. American Journal of Hematology, 2015, 90, 1135-1141.	4.1	66
23	Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine, 2022, 182, 115.	5.1	63
24	A novel role for C3 in antibody-induced red blood cell clearance and antigen modulation. Blood, 2013, 122, 1793-1801.	1.4	62
25	Regulation of primary alloantibody response through antecedent exposure to a microbial T-cell epitope. Blood, 2010, 115, 3989-3996.	1.4	61
26	Antigen Modulation Confers Protection to Red Blood Cells from Antibody through FcÎ <sup>3</sup> Receptor Ligation. Journal of Immunology, 2013, 191, 5013-5025.	0.8	61
27	Transfusion of murine red blood cells expressing the human <scp>KEL</scp> glycoprotein induces clinically significant alloantibodies. Transfusion, 2014, 54, 179-189.	1.6	61
28	Type I IFN Is Necessary and Sufficient for Inflammation-Induced Red Blood Cell Alloimmunization in Mice. Journal of Immunology, 2017, 199, 1041-1050.	0.8	56
29	Antigen Density Dictates Immune Responsiveness following Red Blood Cell Transfusion. Journal of Immunology, 2017, 198, 2671-2680.	0.8	54
30	Red Blood Cell Alloimmunization Mitigation Strategies. Transfusion Medicine Reviews, 2014, 28, 137-144.	2.0	53
31	Discrete Tollâ€like receptor agonists have differential effects on alloimmunization to transfused red blood cells. Transfusion, 2008, 48, 1869-1877.	1.6	50
32	Chronic inflammatory autoimmune disorders are a risk factor for red blood cell alloimmunization. British Journal of Haematology, 2016, 174, 483-485.	2.5	50
33	Contemporary Risk Factors and Outcomes of Transfusion-Associated Circulatory Overload*. Critical Care Medicine, 2018, 46, 577-585.	0.9	48
34	Generation of transgenic mice with antithetical KEL1 and KEL2 human blood group antigens on red blood cells. Transfusion, 2012, 52, 2620-2630.	1.6	47
35	Alloantibodies to a paternally derived RBC KEL antigen lead to hemolytic disease of the fetus/newborn in a murine model. Blood, 2013, 122, 1494-1504.	1.4	47
36	Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood, 2021, 137, 969-976.	1.4	46

Jeanne E Hendrickson

#	Article	IF	CITATIONS
37	CD8+ T cells mediate antibody-independent platelet clearance in mice. Blood, 2016, 127, 1823-1827.	1.4	45
38	Variation in Neonatal Transfusion Practice. Journal of Pediatrics, 2021, 235, 92-99.e4.	1.8	45
39	Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal. Haematologica, 2020, 105, 539-544.	3.5	44
40	Frequency of glucoseâ€6â€phosphate dehydrogenase–deficient red blood cell units in a metropolitan transfusion service. Transfusion, 2013, 53, 606-611.	1.6	43
41	Antigen modulation as a potential mechanism of anti-KEL immunoprophylaxis in mice. Blood, 2016, 128, 3159-3168.	1.4	43
42	Anti-KEL sera prevents alloimmunization to transfused KEL RBCs in a murine model. Haematologica, 2015, 100, e394-e397.	3.5	42
43	Antibody-Mediated Immune Suppression of Erythrocyte Alloimmunization Can Occur Independently from Red Cell Clearance or Epitope Masking in a Murine Model. Journal of Immunology, 2014, 193, 2902-2910.	0.8	41
44	Complement serves as a switch between CD4+ T cell–independent and –dependent RBC antibody responses. JCl Insight, 2018, 3, .	5.0	40
45	Autonomic dysfunction and HPV immunization: an overview. Immunologic Research, 2018, 66, 744-754.	2.9	38
46	Erythrophagocytosis by plasmacytoid dendritic cells and monocytes is enhanced during inflammation. Transfusion, 2016, 56, 905-916.	1.6	37
47	Transfusion of fresh murine red blood cells reverses adverse effects of older stored red blood cells. Transfusion, 2011, 51, 2695-2702.	1.6	36
48	Immune parameter analysis of children with sickle cell disease on hydroxycarbamide or chronic transfusion therapy. British Journal of Haematology, 2015, 169, 574-583.	2.5	36
49	The spleen plays a central role in primary humoral alloimmunization to transfused mHEL red blood cells. Transfusion, 2009, 49, 1678-1684.	1.6	35
50	Red Blood Cell Antibodies in Hematology/Oncology Patients. Hematology/Oncology Clinics of North America, 2016, 30, 635-651.	2.2	35
51	Marginal zone B cells mediate a CD4 T-cell–dependent extrafollicular antibody response following RBC transfusion in mice. Blood, 2021, 138, 706-721.	1.4	34
52	Use of mouse models to study the mechanisms and consequences of RBC clearance. Vox Sanguinis, 2010, 99, 99-111.	1.5	33
53	B cells require Type 1 interferon to produce alloantibodies to transfused KELâ€expressing red blood cells in mice. Transfusion, 2017, 57, 2595-2608.	1.6	32
54	Rapid clearance of transfused murine red blood cells is associated with recipient cytokine storm and enhanced alloimmunogenicity. Transfusion, 2011, 51, 2445-2454.	1.6	31

#	Article	IF	CITATIONS
55	Marginal Zone B Cells Induce Alloantibody Formation Following RBC Transfusion. Frontiers in Immunology, 2018, 9, 2516.	4.8	31
56	Antibody-mediated immune suppression by antigen modulation is antigen-specific. Blood Advances, 2018, 2, 2986-3000.	5.2	31
57	The ethics of a proposed study of hematopoietic stem cell transplant for children with "less severe― sickle cell disease. Blood, 2014, 124, 861-866.	1.4	30
58	Interleukin-6 receptor-alpha signaling drives anti-RBC alloantibody production and T-follicular helper cell differentiation in a murine model of red blood cell alloimmunization. Haematologica, 2016, 101, e440-e444.	3.5	30
59	Complement Component 3 Negatively Regulates Antibody Response by Modulation of Red Blood Cell Antigen. Frontiers in Immunology, 2018, 9, 676.	4.8	30
60	Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Studyâ€III (REDSâ€III). Transfusion, 2019, 59, 217-225.	1.6	30
61	Donor genetic and nongenetic factors affecting red blood cell transfusion effectiveness. JCI Insight, 2022, 7, .	5.0	29
62	Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLoS ONE, 2021, 16, e0254453.	2.5	27
63	Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert Review of Hematology, 2020, 13, 489-499.	2.2	24
64	Alloimmunization to transfused HOD red blood cells is not increased in mice with sickle cell disease. Transfusion, 2012, 52, 231-240.	1.6	23
65	Red blood cell alloimmunization: new findings at the bench and new recommendations for the bedside. Current Opinion in Hematology, 2016, 23, 543-549.	2.5	23
66	Human papilloma virus vaccination and dysautonomia: Considerations for autoantibody evaluation and HLA typing. Vaccine, 2016, 34, 4468.	3.8	22
67	Delayed haemolytic and serologic transfusion reactions. Current Opinion in Hematology, 2018, 25, 459-467.	2.5	22
68	Red blood cell transfusions are associated with <scp>HLA</scp> class I but not H‥ alloantibodies in children with sickle cell disease. British Journal of Haematology, 2015, 170, 247-256.	2.5	21
69	Complex regional pain syndrome and dysautonomia in a 14â€yearâ€old girl responsive to therapeutic plasma exchange. Journal of Clinical Apheresis, 2016, 31, 368-374.	1.3	21
70	The Nlrp3 Inflammasome Does Not Regulate Alloimmunization to Transfused Red Blood Cells in Mice. EBioMedicine, 2016, 9, 77-86.	6.1	20
71	2016 proceedings of the National Heart, Lung, and Blood Institute's scientific priorities in pediatric transfusion medicine. Transfusion, 2017, 57, 1568-1581.	1.6	20
72	Fatal acute hemolytic transfusion reaction due to antiâ€8 from a platelet apheresis unit stored in platelet additive solution. Transfusion, 2019, 59, 1911-1915.	1.6	20

#	Article	IF	CITATIONS
73	Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Transfusion Clinique Et Biologique, 2019, 26, 112-115.	0.4	20
74	Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion, 2017, 57, 289-295.	1.6	19
75	Transfusion practices in a large cohort of hospitalized children. Transfusion, 2021, 61, 2042-2053.	1.6	19
76	CD4 Depletion or CD40L Blockade Results in Antigen-Specific Tolerance in a Red Blood Cell Alloimmunization Model. Frontiers in Immunology, 2017, 8, 907.	4.8	18
77	Variation in vital signs resulting from blood component administration in adults. Transfusion, 2015, 55, 1866-1871.	1.6	16
78	Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey. Leukemia and Lymphoma, 2018, 59, 2723-2726.	1.3	16
79	The Recipient Epidemiology and Donor Evaluation <scp>Studyâ€ŀVâ€Pediatric</scp> ( <scp>REDSâ€ŀVâ€P</scp> ): research program striving to improve blood donor safety and optimize transfusion outcomes across the lifespan. Transfusion, 2022, 62, 982-999.	A 1.6	16
80	Clinically significant antiâ€ <scp>KEL RBC</scp> alloantibodies are transferred by breast milk in a murine model. Vox Sanguinis, 2016, 111, 79-87.	1.5	15
81	Autoimmunity, Autonomic Neuropathy, and the HPV Vaccination: A Vulnerable Subpopulation. Clinical Pediatrics, 2018, 57, 603-606.	0.8	15
82	Type 1 IFN signaling critically regulates influenzaâ€induced alloimmunization to transfused KEL RBCs in a murine model. Transfusion, 2019, 59, 3243-3252.	1.6	15
83	Transfusion Practices in Pediatric Cardiac Surgery Requiring Cardiopulmonary Bypass: A Secondary Analysis of a Clinical Database. Pediatric Critical Care Medicine, 2021, 22, 978-987.	0.5	14
84	Mechanisms of alloimmunization in sickle cell disease. Current Opinion in Hematology, 2019, 26, 434-441.	2.5	13
85	A novel network analysis tool to identify relationships between disease states and risks for red blood cell alloimmunization. Vox Sanguinis, 2017, 112, 469-472.	1.5	12
86	A multicentre study investigating vital sign changes occurring in complicated and uncomplicated transfusions. Vox Sanguinis, 2018, 113, 160-169.	1.5	12
87	TRIX with treats: the considerable safety benefits of a transfusion medicine registry. Transfusion, 2019, 59, 2489-2492.	1.6	12
88	Immunohematologic aspects of alloimmunization and alloantibody detection: A focus on pregnancy and hemolytic disease of the fetus and newborn. Transfusion and Apheresis Science, 2020, 59, 102946.	1.0	12
89	The evanescence and persistence of RBC alloantibodies in blood donors. Transfusion, 2020, 60, 831-839.	1.6	12
90	Preventing transfusionâ€associated graftâ€versusâ€host disease with blood component irradiation: indispensable guidance for a deadly disorder. British Journal of Haematology, 2020, 191, 653-657.	2.5	11

#	Article	IF	CITATIONS
91	Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura. Blood Advances, 2020, 4, 539-545.	5.2	11
92	Riboflavinâ€ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells. Transfusion, 2016, 56, 863-872.	1.6	10
93	Red cell exchange for patients with sickle cell disease: an international survey of current practices. Transfusion, 2020, 60, 1424-1433.	1.6	10
94	Parasite burden and red blood cell exchange transfusion for babesiosis. Journal of Clinical Apheresis, 2021, 36, 127-134.	1.3	10
95	Transfusion practices for pediatric oncology and hematopoietic stem cell transplantation patients: Data from the <scp>National Heart Lung and Blood Institute Recipient Epidemiology and Donor Evaluation Studyâ€III (REDSâ€III)</scp> . Transfusion, 2021, 61, 2589-2600.	1.6	10
96	Clodronate inhibits alloimmunization against distinct red blood cell alloantigens in mice. Transfusion, 2022, 62, 948-953.	1.6	10
97	Routine nonâ€ABO blood group antigen genotyping in sickle cell disease: the new frontier in pretransfusion testing?. Transfusion, 2015, 55, 1374-1377.	1.6	8
98	Measuring the influence of blood component infusion rate on recipient vital signs. Vox Sanguinis, 2015, 109, 353-358.	1.5	8
99	The impact of pre-existing HLA and red blood cell antibodies on transfusion support and engraftment in sickle cell disease after nonmyeloablative hematopoietic stem cell transplantation from HLA-matched sibling donors: A prospective, single-center, observational study. EClinicalMedicine, 2020, 24, 100432.	7.1	8
100	The lysophospholipidâ€binding molecule <scp>CD1D</scp> is not required for the alloimmunization response to fresh or stored <scp>RBCs</scp> in mice despite <scp>RBC</scp> storage driving alterations in lysophospholipids. Transfusion, 2021, 61, 2169-2178.	1.6	8
101	Red blood cell alloimmunization and sickle cell disease: a narrative review on antibody induction. Annals of Blood, 2020, 5, 33-33.	0.4	8
102	Irradiation of Red Blood Cells and Alloimmunization. Laboratory Medicine, 2017, 48, 172-177.	1.2	7
103	Red blood cell alloimmunization is associated with lower expression of FcÎ <sup>3</sup> R1 on monocyte subsets in patients with sickle cell disease. Transfusion, 2019, 59, 3219-3227.	1.6	7
104	COVID-19 and the Coombs test. Blood, 2020, 136, 655-656.	1.4	7
105	Medical marijuana certification for patients with sickle cell disease: a report of a single center experience. Blood Advances, 2020, 4, 3814-3821.	5.2	7
106	Innate and Adaptive Immunity to Transfused Allogeneic RBCs in Mice Requires MyD88. Journal of Immunology, 2022, 208, 991-997.	0.8	7
107	Bortezomib decreases the magnitude of a primary humoral immune response to transfused red blood cells in a murine model. Transfusion, 2017, 57, 82-92.	1.6	6
108	Human leukocyte antigen (HLA) class I antibodies and transfusion support in paediatric HLAâ€matched haematopoietic cell transplant for sickle cell disease. British Journal of Haematology, 2020, 189, 162-170.	2.5	6

#	Article	IF	CITATIONS
109	Characterization of circulating and cultured Tfh-like cells in sickle cell disease in relation to red blood cell alloimmunization status. Transfusion and Apheresis Science, 2020, 59, 102778.	1.0	6
110	Altered type 1 interferon responses in alloimmunized and nonalloimmunized patients with sickle cell disease. EJHaem, 2021, 2, 700-710.	1.0	6
111	Poly(I:C) causes failure of immunoprophylaxis to red blood cells expressing the KEL glycoprotein in mice. Blood, 2020, 135, 1983-1993.	1.4	6
112	Management of hemolytic transfusion reactions. Hematology American Society of Hematology Education Program, 2021, 2021, 704-709.	2.5	6
113	International guidelines regarding the role of IVIG in the management of Rh―and ABOâ€mediated haemolytic disease of the newborn. British Journal of Haematology, 2022, , .	2.5	6
114	A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia. Hematology, 2018, 23, 429-432.	1.5	5
115	A novel association between high red blood cell alloimmunization rates and hereditary hemorrhagic telangiectasia. Transfusion, 2018, 58, 775-780.	1.6	5
116	Complement Plays a Critical Role in Inflammation-Induced Immunoprophylaxis Failure in Mice. Frontiers in Immunology, 2021, 12, 704072.	4.8	5
117	Central T Cell Tolerance and Peripheral B Cell Tolerance for An RBC Autoantigen Are Incomplete in Healthy Mice; Implications for AIHA Pathogenesis. Blood, 2011, 118, 693-693.	1.4	5
118	Determination of Red Blood Cell Alloimmunization Rates in Transfused Patients with Hematologic and Oncologic Malignancies. Blood, 2016, 128, 1463-1463.	1.4	5
119	Innate B-1 B Cells Are Not Enriched in Red Blood Cell Autoimmune Mice: Importance of B Cell Receptor Transgenic Selection. Frontiers in Immunology, 2017, 8, 1366.	4.8	4
120	Red blood cell alloimmunisation: induction of immunity and potential mitigation strategies. ISBT Science Series, 2018, 13, 105-111.	1.1	4
121	Rhesus pieces: genotype matching of RBCs. Blood, 2018, 132, 1091-1093.	1.4	4
122	Very low rate of antiâ€D development in male, primarily immunocompetent patients transfused with Dâ€mismatched platelets. Transfusion, 2018, 58, 1568-1569.	1.6	4
123	Microbial pathogen primary sequence inversely correlates with blood group antigen immunogenicity. Transfusion, 2019, 59, 1651-1656.	1.6	4
124	<scp>NTâ€proBNP</scp> levels in the identification and classification of pulmonary transfusion reactions. Transfusion, 2020, 60, 2548-2556.	1.6	4
125	Therapeutic plasma exchange for peripheral neuropathy associated with trisulfated heparan disaccharide IgM antibodies: A case series of 17 patients. Journal of Clinical Apheresis, 2021, ,	1.3	4
126	North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia. Blood, 2015, 126, 1138-1138.	1.4	4

#	Article	IF	CITATIONS
127	Investigation of increased platelet alloimmunization screening in the era of pathogenâ€reduced platelets treated with psoralen/UV light. Transfusion, 2020, 60, 650-651.	1.6	3
128	Application of PLASMIC score in prediction of ADAMTS13 deficiency in a pediatric case of acquired thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis, 2020, 35, 140-141.	1.3	3
129	Factor V activity in apheresis platelets: Implications for management of FV deficiency. Transfusion, 2021, 61, 405-409.	1.6	3
130	Anti-RhD Mediates Loss of RhD Antigen Following Anti-RhD Infusion. Blood, 2015, 126, 3570-3570.	1.4	3
131	Autologous hematopoietic stem cell product contaminated with <i>Salmonella</i> due to occult salmonellosis in an asymptomatic donor. Journal of Clinical Apheresis, 2022, 37, 316-319.	1.3	3
132	Recipient factors influencing red blood cell alloimmunization. ISBT Science Series, 2020, 15, 194-200.	1.1	2
133	Pediatric Hemovigilance and Adverse Transfusion Reactions. Clinics in Laboratory Medicine, 2021, 41, 51-67.	1.4	2
134	Cost Effectiveness of Rituximab As Adjunctive Therapy in Reducing Apheresis Procedures and Hospital Length of Stay in Relapsed Thrombotic Thrombocytopenic Purpura. Blood, 2018, 132, 3814-3814.	1.4	2
135	Use of Convalescent Plasma Therapy in Severe Coronavirus Disease 2019: The Yale-New Haven Health System Experience. Blood, 2020, 136, 39-40.	1.4	2
136	Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2020, 136, 18-19.	1.4	2
137	Coagulopathy Predicts Mortality in Pediatric Patients with Traumatic Brain Injury. Blood, 2014, 124, 2891-2891.	1.4	2
138	Elevated Levels of CD64 MFI on Monocyte Subsets Are Associated with a History of Stroke in Sickle Cell Disease. Blood, 2018, 132, 1093-1093.	1.4	2
139	Non-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapy. Transfusion and Apheresis Science, 2022, 61, 103304.	1.0	2
140	<scp>RBC</scp> alloimmunization and daratumumab: Are efforts to eliminate interferences and prevent new antibodies necessary?. Transfusion, 2021, 61, 3283-3285.	1.6	2
141	Leukoreduced red blood cell transfusions do not induce platelet glycoprotein antibodies in patients with sickle cell disease. Transfusion, 2016, 56, 2267-2273.	1.6	1
142	The impact of vaccination on <scp>RBC</scp> alloimmunization in a murine model. Vox Sanguinis, 2017, 112, 598-600.	1.5	1
143	Limitations of a scoring model to predict thrombotic thrombocytopaenic purpura. Vox Sanguinis, 2017, 112, 185-186.	1.5	1
144	Transfusion Support of the Patient with Sickle Cell Disease Undergoing Transplantation. , 2018, ,		1

<sup>144</sup> 111-136.

#	Article	IF	CITATIONS
145	Cryoglobulinemia as a Possible Primer for TRALI: Report of a Case. Laboratory Medicine, 2019, 50, 313-319.	1.2	1
146	Passive anti  acquired in the setting of Rh immune globulin administration following Rh mismatched apheresis platelet transfusion: A case series. Journal of Clinical Apheresis, 2020, 35, 224-226.	1.3	1
147	Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection. Transfusion and Apheresis Science, 2021, 60, 103069.	1.0	1
148	Leukoreduction Decreases Alloimmunogenicity of Transfused Murine HOD RBCs Blood, 2009, 114, 640-640.	1.4	1
149	Transfused platelets enhance alloimmune responses to transfused KEL-expressing red blood cells in a murine model. Blood Transfusion, 2019, 17, 368-377.	0.4	1
150	Transfusion Medicine. Hematology/Oncology Clinics of North America, 2016, 30, xiii-xiv.	2.2	0
151	Platelet and plasma transfusions for infants and children. , 2016, , 542-548.		Ο
152	Preanalytical errors in transfusion medicine: Reply to "74-year-old female with new monoclonal protein on serum immunofixation electrophoresis― Clinical Biochemistry, 2017, 50, 1334-1335.	1.9	0
153	9 Examining the Correlation Between Microbial Pathogen Sequence Structure and Blood Group Antigen Immunogenicity. American Journal of Clinical Pathology, 2018, 149, S167-S168.	0.7	Ο
154	1 Type I Interferon Is Necessary and Sufficient for Alloimmunization to Transfused KEL-Expressing RBCs in Mice. American Journal of Clinical Pathology, 2018, 149, S163-S163.	0.7	0
155	Tollâ€like receptor SNPs and sickle cell disease: a PRRfect storm for RBC alloimmunization. British Journal of Haematology, 2019, 186, 803-804.	2.5	Ο
156	Development of anti-Jk3 associated with silenced Kidd antigen expression and a novel single nucleotide variant of the <i>JK</i> gene. Immunohematology, 2021, 37, 109-112.	0.2	0
157	Host Inflammation Increases Alloimmunization to Transfused Red Blood Cells Blood, 2005, 106, 1887-1887.	1.4	Ο
158	A Novel Model of Autoimmunity to Self Red Blood Cell Antigens. Blood, 2008, 112, 3461-3461.	1.4	0
159	CD8+ T Cells Mediate Antibody-Independent Platelet Clearance Following Transfusion. Blood, 2014, 124, 596-596.	1.4	Ο
160	Reticuloendothelial Saturation Dictates the Development of RBC Resistance to Antibody-Mediated Clearance Following Incompatible Transfusion. Blood, 2014, 124, 1559-1559.	1.4	0
161	Chronic Inflammatory Autoimmune Disorders Are a Risk Factor for Blood Group Alloimmunization in Transfused Patients. Blood, 2014, 124, 4294-4294.	1.4	0
162	NLRP10-Deficient Mice Reveal a Crucial Role for Dendritic Cell Activity in the Initiation of the Allogeneic Response to Transfused Red Blood Cells. Blood, 2014, 124, 4113-4113.	1.4	0

#	Article	IF	CITATIONS
163	Antigen Density Impacts RBC Survival and Antigen Modulation Following Incompatible RBC Transfusion. Blood, 2015, 126, 2350-2350.	1.4	0
164	DOCK8-Deficient Mice Reveal a Crucial Role for Dendritic Cell Activity in the Initiation of the Allogeneic Response to Transfused Red Blood Cells. Blood, 2015, 126, 658-658.	1.4	0
165	A Novel Network Analysis Tool to Identify Relationships Between Disease States and Risk for RBC Alloimmunization. Blood, 2015, 126, 2349-2349.	1.4	0
166	Influenza Infection Induces RBC Alloimmunization By a Type 1 Interferon Dependent Mechanism. Blood, 2018, 132, 743-743.	1.4	0
167	HLA Class I Alloimmunization and Platelet Transfusion Support in HLA-Identical Bone Marrow Transplant for Sickle Cell Disease: A Sickle Transplant Alliance for Research Study. Blood, 2018, 132, 3816-3816.	1.4	0
168	Increased Expression of Type 1 Interferon Stimulated Genes in Sickle Cell Disease and a Potential Association with RBC Alloimmunization. Blood, 2019, 134, 716-716.	1.4	0
169	Baseline Pain in Adults with Sickle Cell Disease Can be Neuropathic or Nociceptive and Outcomes Differ between Pain Types. Blood, 2019, 134, 1028-1028.	1.4	0
170	The Presence and Persistence of Pregnancy-Associated Red Blood Cell Alloantibodies in Blood Donors. Blood, 2019, 134, 2452-2452.	1.4	0
171	Potential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell Disease. Frontiers in Medicine, 2021, 8, 679030.	2.6	0
172	Co-Culture of Acinetobacter calcoaceticus-baumannii complex and Staphylococcus saprophyticus Supports Simple Point Contamination Model in Recent Cases of Transfusion-Related Sepsis. American Journal of Clinical Pathology, 2020, 154, S14-S14.	0.7	0
173	Optimization of Plerixafor Utilization Based on Peripheral Blood CD34+ Count for Autologous Peripheral Blood Stem-Cell Collection. Blood, 2020, 136, 41-41.	1.4	0
174	Type I Interferon Gene Signature in Peripheral Blood Mononuclear Cells of Sickle Cell Disease Patients and a Connection to RBC Alloimmunization. Blood, 2020, 136, 26-27.	1.4	0